Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590140800> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- W2590140800 endingPage "11532" @default.
- W2590140800 startingPage "11532" @default.
- W2590140800 abstract "11532 Background: The gemcitabine and cisplatin doublet has been frequently used in advanced breast cancer. However, the use of gemcitabine and cisplatin concomitant with anastrozole has not been studied well in Asian women. The objective of this study was to evaluate the efficacy and toxicity of concomitant gemcitabine-cisplatin-anastrozole chemo-hormonal treatment in postmenopausal women with locally advanced breast cancer. Methods: Histopathologically documented female breast cancers with locally advanced UICC stage III disease and a KPS > 70 were eligible. Patients were required to be postmenopausal, hormone receptor positive and Her 2 Neu negative. Adequate marrow, renal and hepatic function was required. Anastrozole 1 mg was given daily. Gemcitabine 1,250 mg/m2 was given on day 1 & 8 with cisplatin 70 mg/m2 on day 1 of three weekly cycles. CTCAE version 3.0 of NCI and RECIST was used. All patients underwent MRM after four cycles. Miller and Payene criteria was used for evaluation of pathologic response. Results: From January 2006 to December 2007, 25 patients were enrolled. Median age was 47 years (Range 28–70). Pathologic complete response was seen in 4 (16 %) patients and partial response in 19 (76 %) with an overall response rate of 92 %. One patient ( 4%) had stable disease and one patient ( 4%) developed progressive disease during treatment. Grade 2 neutropenia, thrombocytopenia, vomiting and serum creatinine elevation was seen in 32 %, 12%, 28% and 16 %, respectively. Grade 3 neutropenia and vomiting was seen in 20 % and 4 %, respectively. Persistent grade 2 arthralgia was seen in 28 % and myalgia in 20 %. Conclusions: This treatment schedule is an effective first line treatment of LABC patients and provides an excellent overall pathologic response rate and manageable toxicity. No significant financial relationships to disclose." @default.
- W2590140800 created "2017-03-03" @default.
- W2590140800 creator A5005625794 @default.
- W2590140800 creator A5012269259 @default.
- W2590140800 creator A5049803544 @default.
- W2590140800 creator A5057492619 @default.
- W2590140800 date "2008-05-20" @default.
- W2590140800 modified "2023-09-24" @default.
- W2590140800 title "Gemcitabine-cisplatin-anastrozole concomitant chemo-hormonal treatment in locally advanced breast cancer in postmenopausal women" @default.
- W2590140800 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.11532" @default.
- W2590140800 hasPublicationYear "2008" @default.
- W2590140800 type Work @default.
- W2590140800 sameAs 2590140800 @default.
- W2590140800 citedByCount "0" @default.
- W2590140800 crossrefType "journal-article" @default.
- W2590140800 hasAuthorship W2590140800A5005625794 @default.
- W2590140800 hasAuthorship W2590140800A5012269259 @default.
- W2590140800 hasAuthorship W2590140800A5049803544 @default.
- W2590140800 hasAuthorship W2590140800A5057492619 @default.
- W2590140800 hasConcept C121608353 @default.
- W2590140800 hasConcept C126322002 @default.
- W2590140800 hasConcept C143998085 @default.
- W2590140800 hasConcept C2776215463 @default.
- W2590140800 hasConcept C2776694085 @default.
- W2590140800 hasConcept C2777063308 @default.
- W2590140800 hasConcept C2777176818 @default.
- W2590140800 hasConcept C2779384505 @default.
- W2590140800 hasConcept C2780258809 @default.
- W2590140800 hasConcept C530470458 @default.
- W2590140800 hasConcept C71924100 @default.
- W2590140800 hasConcept C90924648 @default.
- W2590140800 hasConceptScore W2590140800C121608353 @default.
- W2590140800 hasConceptScore W2590140800C126322002 @default.
- W2590140800 hasConceptScore W2590140800C143998085 @default.
- W2590140800 hasConceptScore W2590140800C2776215463 @default.
- W2590140800 hasConceptScore W2590140800C2776694085 @default.
- W2590140800 hasConceptScore W2590140800C2777063308 @default.
- W2590140800 hasConceptScore W2590140800C2777176818 @default.
- W2590140800 hasConceptScore W2590140800C2779384505 @default.
- W2590140800 hasConceptScore W2590140800C2780258809 @default.
- W2590140800 hasConceptScore W2590140800C530470458 @default.
- W2590140800 hasConceptScore W2590140800C71924100 @default.
- W2590140800 hasConceptScore W2590140800C90924648 @default.
- W2590140800 hasIssue "15_suppl" @default.
- W2590140800 hasLocation W25901408001 @default.
- W2590140800 hasOpenAccess W2590140800 @default.
- W2590140800 hasPrimaryLocation W25901408001 @default.
- W2590140800 hasRelatedWork W1972888300 @default.
- W2590140800 hasRelatedWork W1995827211 @default.
- W2590140800 hasRelatedWork W2020627042 @default.
- W2590140800 hasRelatedWork W2034377028 @default.
- W2590140800 hasRelatedWork W2058494984 @default.
- W2590140800 hasRelatedWork W2113053783 @default.
- W2590140800 hasRelatedWork W2590140800 @default.
- W2590140800 hasRelatedWork W2599190269 @default.
- W2590140800 hasRelatedWork W2939092495 @default.
- W2590140800 hasRelatedWork W3039479925 @default.
- W2590140800 hasVolume "26" @default.
- W2590140800 isParatext "false" @default.
- W2590140800 isRetracted "false" @default.
- W2590140800 magId "2590140800" @default.
- W2590140800 workType "article" @default.